Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples.
Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples.
复制标题
DOI：
10.3892/ijo_00000763
复制
发表时间：
2010-11
影响因子：
5.2
通讯作者：
M. Motoori;I. Takemasa;M. Yamasaki;T. Komori;A. Takeno;H. Miyata;S. Takiguchi;Y. Fujiwara;T. Yasuda;M. Yano;N. Matsuura;K. Matsubara;M. Monden;M. Mori;Y. Doki
中科院分区：
文献类型：
--
作者：
M. Motoori;I. Takemasa;M. Yamasaki;T. Komori;A. Takeno;H. Miyata;S. Takiguchi;Y. Fujiwara;T. Yasuda;M. Yano;N. Matsuura;K. Matsubara;M. Monden;M. Mori;Y. Doki
为了改善晚期食管癌的预后，手术加新辅助化疗是一种很有前景的治疗策略。NACT已被证明可以改善应答者的预后。然而，无反应者不仅遭受副作用，而且还失去了宝贵的时间来利用其他可能的治疗方法。因此，建立一种可靠的方法来预测化疗前的反应是至关重要的。活检样本可以提供个体食管癌生物学特征的有价值信息，这可能影响化疗敏感性。本文对25例接受顺铂化疗的食管鳞状细胞癌（ESCC）患者的50个预处理内镜活检样本（每位患者2个样本）进行了覆盖30,000个人体探针的寡核苷酸微阵列综合基因表达谱分析（GEP）。通过CT扫描肿瘤面积的缩小率来评估化疗反应。缓解者定义为缓解率≥50%的患者，无缓解者定义为缓解率<50%的患者。预测化疗反应的诊断系统是用199个信息量最大的基因构建的，准确率为82%。此外，使用额外的10个样本验证了该系统的预测性能，准确率为80%。本研究表明，预处理ESCC活检样本的GEP具有预测化疗反应的潜力。
To improve the prognosis of advanced esophageal cancer, neoadjuvant chemotherapy (NACT) followed by surgery is a promising treatment strategy. NACT has been shown to improve the prognosis of responders. However, non-responders not only suffer from side-effects, but they also lose precious time to take advantage of other possible treatments. Therefore, it is crucial to establish a reliable method that allows prediction of response before chemotherapy. A biopsy sample can provide valuable information on the biological characteristics of an individual esophageal cancer, which can affect chemosensitivity. Comprehensive gene expression profiling (GEP) using oligonucleotide microarray covering 30,000 human probes was performed in 50 pretreatment endoscopic biopsy samples from 25 patients with esophageal squamous cell cancer (ESCC) who underwent cisplatin-based chemotherapy (two samples per patient). Chemotherapeutic responses were evaluated by the reduction rate of the tumor area on CT scans. Responders were defined as patients with reduction rates of ≥50% and non-responders were defined as patients with <50% decrease. The diagnostic system, that predicts responses to chemotherapy, was constructed with the 199 most informative genes, and showed 82% of accuracy. Furthermore, the predictive performance of this system was confirmed using an additional ten samples with an accuracy of 80%. This study shows that GEP of pretreatment ESCC biopsy samples has the potential to predict responses to chemotherapy.